Background: Chronic heart failure (CHF) has a high mortality and morbidity. Large scale RCTs
have proven the benefits of beta blockade (BB) and ACE inhibitors (ACEI) in reducing
mortality in patients with CHF and expert guidelines mandate their use. In spite of
these recommendations, important therapies are under-prescribed and under-utilised.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2007 Published by Elsevier Inc.
